What are IMFINZI + IMJUDO?

IMFINZI, together with IMJUDO for the first dose, followed by IMFINZI alone, is an immunotherapy treatment for adults with unresectable hepatocellular carcinoma (uHCC), a type of liver cancer.

IMFINZI and IMJUDO are not chemotherapy medicines.

IMFINZI is given with one dose of IMJUDO on Day 1, followed by infusions of IMFINZI alone every 4 weeks.

IMFINZI, together with IMJUDO for the first dose, followed by IMFINZI alone, is an immunotherapy treatment for adults with unresectable hepatocellular carcinoma (uHCC), a type of liver cancer.

IMFINZI and IMJUDO are not chemotherapy medicines.

IMFINZI is given with one dose of IMJUDO on Day 1, followed by infusions of IMFINZI alone every 4 weeks.

How were IMFINZI + IMJUDO studied?

A clinical trial included 2 groups of people with uHCC whose liver cancer wasn’t previously treated.

393 people
received IMFINZI + IMJUDO

389 people
received sorafenib

The main goal of this study was to measure overall survival, which is the amount of time patients were living after the start of treatment. Patients in this study included those who may have had disease outside the liver or who had advanced disease in the liver.

IMFINZI + IMJUDO provides patients with hope for longer life with uHCC, a type of liver cancer:

Median Overall Survival

16

months

for people taking IMFINZI + IMJUDO

Median Overall Survival Comparison Icon

14

months

for people taking sorafenib alone

IMFINZI + IMJUDO reduced the risk of death by 22% compared to sorafenib.

The study compared median overall survival, which is the length of time from the start of treatment to the time that half of the people are living. Half of the patients receiving IMFINZI and IMJUDO were living for 16 months, compared to 14 months for patients treated with sorafenib.

Data cutoff was August 27, 2021.

The first and only combination immunotherapy with ~6-year follow-up results in uHCC

In a follow-up analysis at 6 years:

17%

of people who received IMFINZI + IMJUDO were still living

9%

of people who received sorafenib were still living

A follow-up analysis, which is called a post-hoc analysis, was done with a group of people from this original clinical trial. This analysis was conducted approximately 6 years after the last patient started treatment in this study and measured overall survival at 6 years. Given the nature of this disease, fewer patients were evaluated in this analysis. Based on the limitations of the follow-up analysis, results are descriptive and your experience may differ.

Data cutoff was March 1, 2024.

20% of the patients in the study who were on IMFINZI + IMJUDO saw their tumors shrink

20%

People taking IMFINZI + IMJUDO

79/393 patients

Median Overall Survival Comparison Icon

5%

People taking sorafenib

20/389 patients

The study included 393 patients taking IMFINZI + IMJUDO and 389 patients taking sorafenib. 79 patients taking IMFINZI + IMJUDO and 20 patients taking sorafenib saw their tumors shrink.

Based on the limits of the analysis, results are descriptive only, and your experience may differ.

Data cutoff was August 27, 2021.

Start the conversation with your doctor

Ask about IMFINZI + IMJUDO

Important Safety Information

What is the most important information I should know about IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl)?

IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and IMJUDO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

What are IMFINZI and IMJUDO?

IMFINZI is a prescription medicine used in combination with IMJUDO to treat adults with a type of liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).

It is not known if IMFINZI and IMJUDO are safe and effective in children.

  • Lung Problems Icon

    Lung problems: cough, shortness of breath, and chest pain

  • Intestinal Problems Icon

    Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness

  • uHCC Liver Problem Icon

    Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), and bleeding or bruising more easily than normal

  • uHCC Hormone Gland Problems Icon

    Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

  • uHCC Kidney Problems Icon

    Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, and loss of appetite

  • uHCC Skin Problems Icon

    Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; and swollen lymph nodes

  • uHCC Pancreas Problems Icon

    Pancreas problems: pain in your upper stomach area (abdomen), severe nausea or vomiting, and loss of appetite

  • uHCC Patient Icon

    Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with IMFINZI and IMJUDO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: Chest pain, irregular heartbeats, shortness of breath or swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems; tingling or numbness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eye sight; persistent or severe muscle pain or weakness, muscle cramps, joint pain, joint stiffness or swelling; and low red blood cells and bruising

  • uHCC Patient Icon

    Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, and back or neck pain

  • Immune System Rejecting a Transplanted Organ Icon

    Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had

  • uHCC Complications Icon

    Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with IMFINZI. Your healthcare provider will monitor you for these complications

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI and IMJUDO. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI and IMJUDO if you have severe side effects

Before you receive IMFINZI and IMJUDO, tell your healthcare provider about all of your medical conditions, including if you:

  • have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
  • have received an organ or tissue transplant, including corneal transplant
  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment to your chest area
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. IMFINZI and IMJUDO can harm your unborn baby

    Females who are able to become pregnant:

    • Your healthcare provider will give you a pregnancy test before you start treatment with IMFINZI and IMJUDO.
    • You should use an effective method of birth control during your treatment and for 3 months after the last dose of IMFINZI and IMJUDO. Talk to your healthcare provider about birth control methods that you can use during this time.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with IMFINZI and IMJUDO.
  • are breastfeeding or plan to breastfeed. It is not known if IMFINZI and IMJUDO pass into your breast milk. Do not breastfeed during treatment and for3 months after the last dose of IMFINZI and IMJUDO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMFINZI and IMJUDO?

IMFINZI and IMJUDO can cause serious side effects (see above).

The most common side effects of IMFINZI and IMJUDO in adults with unresectable hepatocellular carcinoma (uHCC) include rash, diarrhea, feeling tired, itchiness, muscle or bone pain, and stomach (abdominal) pain.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI and IMJUDO. Ask your healthcare provider or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products Report side effects related to AstraZeneca products. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-10881-800-FDA-1088.

Please see Full Prescribing Information including Medication Guide for IMFINZI and IMJUDO.

What are IMFINZI and IMJUDO?

IMFINZI is a prescription medicine used in combination with IMJUDO to treat adults with a type of liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC)

It is not known if IMFINZI and IMJUDO are safe and effective in children.

Please see Full Prescribing Information including Medication Guide for IMFINZI and IMJUDO.

Top
Mask
Minimize

Important Safety Information

What is the most important information I should know about IMFINZI® (durvalumab) and IMJUDO® (tremelimumab-actl)?

IMFINZI and IMJUDO are medicines that may treat certain cancers by working with your immune system. IMFINZI and IMJUDO can...

IMFINZI and IMJUDO are medicines that...

Read full Important Safety Information

What are IMFINZI and IMJUDO?

IMFINZI is a prescription medicine used in combination with IMJUDO to treat adults with a type of liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma or uHCC).

United States flag iconThis product information is intended for US consumers only.

IMFINZI and IMJUDO are registered trademarks and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.

©2025 AstraZeneca. All rights reserved. US-96496 Last Updated 12/25